Relevium Significantly Strengthens its JV Operations by Entering Into an Agreement to Acquire 100% of Terry Booth’s MED PPE CANADA
Relevium Significantly Strengthens its JV Operations by Entering Into an Agreement to Acquire 100% of Terry Booth’s MED PPE CANADA
MONTREAL, Nov. 23, 2021 (GLOBE NEWSWIRE) -- RELEVIUM TECHNOLOGIES INC. (TSX.V:"RLV", OTCQB:"RLLVF" and Frankfurt: "6BX") (the "Company" or "Relevium"), a company operating in the Personal Protective Equipment ("PPE) sector, is pleased to announce today it has entered into a non-binding term sheet ("Term Sheet") in respect of a proposed acquisition of all the issued and outstanding shares of MED PPE CANADA INC. ("Med PPE"), a distributor of medical equipment, purification systems, and PPE and supplies to the Canadian market.
蒙特利爾,2021年11月23日(環球通訊社)-RELEVIUM Technologies Inc.(TSX.V:“RLV”,OTCQB:“RLLVF”和法蘭克福:“6BX”)(The“公司" 或"Relevium),經營個人防護用品()的公司個人防護裝備)部門,今天很高興地宣佈,它已經簽訂了一份不具約束力的條款説明書(“條款説明書“)就建議收購的全部已發行及已發行股份Med PPE加拿大公司. ("醫用PPE“),一家向加拿大市場銷售醫療設備、淨化系統、個人防護用品和用品的分銷商。
MED PPE CANADA INC.
Med PPE加拿大公司
Med PPE is a privately held, Edmonton-based corporation formed in April 2020 to focus on global market demand and supply of PPE products. Med PPE is a fully licensed distributor of PPE equipment as well as purification systems, and is currently pursuing all forms of PPE, utilizing multiple international resources and procurement opportunities. Med PPE has established a fully licensed facility to operate within the PPE sector, allowing direct selling to all levels of government, professional and medical institutions in Canada.
Med PPE是一家總部位於埃德蒙頓的私人持股公司,成立於2020年4月,專注於全球市場對PPE產品的需求和供應。Med PPE是一家獲得完全許可的PPE設備和淨化系統分銷商,目前正在利用多種國際資源和採購機會尋求各種形式的PPE。Med PPE已經建立了一個在PPE部門內運營的完全許可的設施,允許直接向加拿大各級政府、專業和醫療機構銷售產品。
STRATEGIC SYNERGY
戰略協同
The accretive acquisition of MED PPE will greatly strengthen Relevium's existing PPE business, which has primarily focused on business supply channels into the North American market. The combined business will allow Relevium to aggressively pursue and secure government and institutional PPE tenders through its established state-of-the-art logistics platform, as well as utilization and distribution of air purification and disinfection technologies. MED PPE, along with Relevium and its partners, will allow for greater cross-border North American business opportunities, and leverage strategic sales and marketing channels.
對MED PPE的增值收購將大大加強Relevium現有的PPE業務,該業務主要專注於進入北美市場的業務供應渠道。合併後的業務將使Relevium能夠通過其建立的最先進的物流平臺,以及空氣淨化和消毒技術的利用和分銷,積極爭取政府和機構的PPE投標。Med PPE與Relevium及其合作伙伴一起,將提供更多的北美跨境商機,並利用戰略銷售和營銷渠道。
Aurelio Useche, CEO of Relevium stated: "The addition of MED PPE and its team to Relevium is a significant step to validating our current business strategy in providing a "stable" and "trusted" source of essential medical supplies and PPE to the North American markets. We are excited to work with Mr. Booth and his team of professionals, and we look forward to the successful completion of this transaction."
Relevium首席執行官Aurelio Useche表示:“MED PPE及其團隊加入Relevium是驗證我們目前的業務戰略的重要一步,我們將提供穩定“和”信得過向北美市場供應基本醫療用品和個人防護用品的供應商。我們很高興能與布斯先生和他的專業團隊合作,我們期待着這筆交易的成功完成。“
Terry Booth, CEO of MED PPE stated: "We are excited to join forces with Relevium and to expand our combined business beyond the scope of the ongoing pandemic. As the new business combination continues to execute on plan, we are ready to provide solid and predictable sourcing for various medical supplies, both to the Canadian market, as well as expansion and support to ongoing efforts in the United States and beyond." Booth added: "We expect that with Relevium and our science teams our penetration into air quality system markets will have a significant impact on reducing the risk of any viral disease spread and result in shareholder value."
MED PPE首席執行官特里·布斯(Terry Booth)表示:“我們很高興能與Relevium聯手,並將我們合併後的業務擴展到正在進行的疫情範圍之外。隨着新的業務合併繼續按計劃執行,我們準備為各種醫療用品提供可靠和可預測的來源,包括加拿大市場,以及對美國和其他地區正在進行的努力的擴展和支持。”布斯補充説:“我們預計,通過Relevium和我們的科學團隊,我們對空氣質量系統市場的滲透將對降低任何病毒性疾病傳播的風險產生重大影響,並帶來股東價值。”
Foundation Markets Inc., a Toronto based boutique investment bank and Exempt Market Dealer is acting as advisor to the Company on this transaction.
總部設在多倫多的精品投資銀行和免税市場交易商Foundation Markets Inc.在這筆交易中擔任該公司的顧問。
TRANSACTION TERMS
交易條款
Under the terms of the proposed transaction the Company would acquire all of the outstanding shares of Med PPE for an initial consideration of $2,400,000 payable through the issuance of 120,000,000 common shares in the capital of the Company on closing and an earnout purchase price of up to $8,566,000, payable upon the achievement of certain Revenue and EBITDA targets for the Med PPE business for the 2021 and 2022 calendar years (the "Earnout Payments").
根據擬議交易的條款,公司將以2400000美元的初步代價收購Med PPE的全部流通股,初步代價是在交易完成時發行1.2億股公司股本中的普通股,並支付溢價收購價格。最高可達8,566,000美元,在實現Med PPE業務2021年和2022年的某些收入和EBITDA目標時支付(分紅付款").
Under the proposed terms, the vendors of the Med PPE shares would receive (i) a $500,000 Earnout Payment if the Med PPE revenue for 2021 is $7,200,000 and the amount of this Earnout Payment would increase by $0.16 for every $1 of revenue exceeding the $7,200,000 target, to a maximum of $1,000,000; (ii) a $375,000 Earnout Payment if the Med PPE EBITDA margin is equal to or greater than 5% for 2021 and the amount of this Earnout Payment would increase by $150,000 for every 1% of EBITDA margin above 5%, to a maximum of $1,500,000; (iii) a $1,000,000 Earnout Payment if the Med PPE revenue for 2022 is $9,800,000 and the amount of this Earnout Payment will increase or decrease by $0.10 for every $1 of revenue above or below the $9,800,000 target, to a maximum of $2,000,000; and (iv) a $500,000 Earnout Payment if the Med PPE EBITDA for 2022 is $300,000 and the amount of this Earnout Payment would increase or decrease by $3.33 for every $1 of EBITDA above or below the $300,000 target, to a maximum of $1,666,000 and with no Earnout Payment being paid for this item if EBITDA for 2022 is less than $225,000.
根據擬議條款,如果2021年Med PPE的收入為7,200,000美元,則Med PPE股票的賣家將獲得500,000美元的溢價付款,每超過7,200,000美元的目標收入每1美元,這筆溢價付款的金額將增加0.16美元,最高可達1,000,000美元;(Ii)如果Med PPE EBITDA利潤率等於或大於2021年的5%,則Med PPE股票的賣家將獲得375,000美元的溢價付款,這筆溢價金額將增加0.16美元,達到最高1,000,000美元;(Ii)如果Med PPE EBITDA利潤率等於或大於2021年的5%,則此項溢價付款為375,000美元(Iii)如2022年Med PPE的收入為9800,000元,則可獲100萬元的額外支付金,而該項額外支付額每高於或低於9800,000元的目標收入每增加或減少0.1美元,即可增加或減少0.1美元,至最高200萬元;及。(Iv)如2022年的Med PPE EBITDA為300,000美元,則此項額外支付額為每1元EBITDA增加或減少3.33美元;及。(Iv)如2022年的Med PPE EBITDA為300,000美元,則此項額外支付額每增加或減少1元EBITDA,則增加或減少0.10元,至最高2,000,000元。
The Earnout Payments would be payable in common shares of the Company with the number of shares to be issued being calculated based on the volume weighted average trading price of the common shares of the Company for the 10 days preceding the date of issuance.
溢價將以本公司普通股支付,將發行的股票數量將根據發行日期前10日本公司普通股的成交量加權平均交易價計算。
Completion of the transaction is subject to customary closing conditions including the completion of due diligence, negotiation of definitive agreements and receipt of all necessary regulatory approvals including, without limitation, approval of the TSX Venture Exchange. There is no guarantee that the proposed transaction will be completed on the terms set forth herein or at all.
交易的完成取決於慣常的成交條件,包括完成盡職調查、談判最終協議和獲得所有必要的監管批准,包括但不限於多倫多證券交易所創業板(TSX)的批准。不能保證擬議的交易將按照本文規定的條款完成,或者根本不能保證。
About Relevium Technologies
Relevium技術公司簡介
Relevium Technologies Inc., is a publicly traded company, focused on international procurement, logistics, and delivery of PPE into the North American marketplace. Utilizing trusted vendors and suppliers, and integrating a comprehensive, state-of-the-art supply chain, Artificial Intelligence, and Blockchain technology, enables a highly secure and compliant platform for delivery of PPE equipment to governments, hospitals, foundations, and various institutions.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Relevium Technologies Inc.是一家上市公司,專注於PPE的國際採購、物流和向北美市場的交付。利用值得信賴的供應商和供應商,並集成全面、最先進的供應鏈、人工智能和區塊鏈技術,為向政府、醫院、基金會和各種機構交付個人防護設備提供了一個高度安全和合規的平臺。
兩樣 這個 甲硫氨酸 風險投資 交易所 也不是 它的 監管服務 提供商 (作為 那 術語 是 已定義 在……裏面 多倫多證券交易所創業板政策)對此的充分性或準確性承擔責任 放手。
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisition and the terms thereof, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur".
有關前瞻性陳述的注意事項
本新聞稿包括某些陳述和信息,這些陳述和信息可能構成適用於加拿大證券法的前瞻性信息。除有關歷史事實的陳述外,本新聞稿中的所有陳述(包括有關未來估計、計劃、目標、假設或對未來業績的預期的陳述,包括擬議收購的時間和完成及其條款)均為前瞻性陳述,包含前瞻性信息。一般而言,前瞻性陳述和信息可以通過使用“打算”或“預期”等前瞻性術語或某些行動、事件或結果“可能”、“可能”、“應該”、“將”或“發生”的詞語和短語的變體來識別。
Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will be able to satisfy the conditions to complete the proposed acquisition.
前瞻性陳述基於公司作出的某些重大假設和分析,以及截至本新聞稿發佈之日管理層的意見和估計,包括公司將能夠滿足完成擬議收購的條件的假設。
These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the Company is unable to satisfy the conditions of closing the proposed acquisition including receipt of all necessary regulatory approvals.
這些前瞻性陳述會受到已知和未知的風險、不確定性和其他因素的影響,這些風險、不確定性和其他因素可能會導致公司的實際結果、活動水平、業績或成就與這些前瞻性陳述或前瞻性信息中明示或暗示的內容大不相同。可能導致實際結果不同的重要因素,包括但不限於,公司無法滿足完成擬議收購的條件(包括獲得所有必要的監管批准)的風險。
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbour.
儘管公司管理層試圖找出可能導致實際結果與前瞻性陳述或前瞻性信息中包含的結果大不相同的重要因素,但也可能有其他因素導致結果與預期、估計或預期的結果大不相同。不能保證這些陳述將被證明是準確的,因為實際結果和未來事件可能與這些陳述中預期的大不相同。因此,讀者不應過分依賴前瞻性陳述和前瞻性信息。提醒讀者,依賴此類信息可能不適合用於其他目的。除非依照適用的證券法,否則公司不承諾更新本文中引用的任何前瞻性陳述、前瞻性信息或財務展望。我們在尋找安全的避風港。
On Behalf of the Board of Directors
我謹代表董事會
RELEVIUM TECHNOLOGIES INC.
RELEVIUM技術 公司
Aurelio Useche
President and CEO
奧雷裏奧·烏塞切
總裁兼首席執行官
For more information about this press release: Tel: +1.888.528.8687
欲瞭解有關本新聞稿的更多信息,請致電:+1.888.528.8687。
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.comWebsite: www.releviumtechnologies.comLike us on Facebook
Follow us on TwitterFollow us on LinkedIn
RELEVIUM技術公司
電子郵件:郵箱:Investors@eleviumcorp.com網站:www.ease viumtechnology ologies.com在Facebook上點讚我們
在推特上關注我們在LinkedIn上關注我們
譯文內容由第三人軟體翻譯。
評論(0)
請選擇舉報原因